-+ 0.00%
-+ 0.00%
-+ 0.00%
According to a research report published by Nomura, Kang Fang Biotech's overseas partner Summit announced that the US FDA did not approve its application for approval of the PD-1/VEGF bispecific antibody iVonescimab for use in EGFR mutant non-small cell lung cancer after treatment with TKI. The full response letter indicated that there was a lack of statistically significant overall survival improvement as the reason for the rejection. The bank pointed out that the main analysis of the Harmoni trial did not reach one of the OS endpoints. Although there were favorable OS updates thereafter, the FDA still refused approval on the grounds that there were no significant OS improvements. This is the first time that the drug has failed in an overseas BLA. As a result, the bank lowered its overseas outlook, and indicated that domestic growth was also slowing down. The rating was downgraded from “buy” to “neutral”, and the target price was lowered from HK$138.29 to HK$94.
Share
Listen to the news
According to a research report published by Nomura, Kang Fang Biotech's overseas partner Summit announced that the US FDA did not approve its application for approval of the PD-1/VEGF bispecific antibody iVonescimab for use in EGFR mutant non-small cell lung cancer after treatment with TKI. The full response letter indicated that there was a lack of statistically significant overall survival improvement as the reason for the rejection. The bank pointed out that the main analysis of the Harmoni trial did not reach one of the OS endpoints. Although there were favorable OS updates thereafter, the FDA still refused approval on the grounds that there were no significant OS improvements. This is the first time that the drug has failed in an overseas BLA. As a result, the bank lowered its overseas outlook, and indicated that domestic growth was also slowing down. The rating was downgraded from “buy” to “neutral”, and the target price was lowered from HK$138.29 to HK$94.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending